v3.26.1
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)
6 Months Ended
Jun. 30, 2026
Supplementary Financial Statement Information [Abstract]  
Schedule of Revenues
   

Six months ended

June 30

   

Three months ended

June 30 

 
    2025

    2026    

2025

    2026  
Royalties revenue   $ 683     $ -     $ 530     $ -  
Sale of IP and license revenue     17,577       568       16,717       460  
Support services     32       131       14       131  
Total revenue   $ 18,292     $ 699     $ 17,261     $ 591  
Schedule of Research and Development Expenses
   

Six months ended

June 30 

   

Three months ended 

June 30 

 
    2025     2026     2025     2026  
Payroll and related expenses   $ 1,687     $ 2,083     $ 763     $ 1,026  
Clinical and preclinical trials expenses     3,660       1,992       1,850       1,590  
Professional consulting and subcontracted work     4,722       1,819       1,656       797  
Supplier-led manufacturing development     2,749       -       -       -  
Other     671       611       377       306  
Total Research and development expenses   $ 13,489     $ 6,505     $ 4,646     $ 3,719